Looks like you clickedhttps://www.orion.fi/en/Orion-group/media/stock-exchange-releases/2018/orion-and-bayer-have-completed-the-phase-iii-trial-of-darolutamide-in-patients-with-non-metastatic-castration-resistant-prostate-cancer---the-primary-endpoint-was-met/
If you do not want to visit that page, you can close this browser tab.
